PharmaTimes June 19, 2025
Signadori is advancing a platform designed to overcome the challenges of treating solid cancers
eXmoor Pharma and Signadori Bio have entered into a partnership aimed at advancing a gene-modified monocyte-derived macrophage cell therapy programme for solid tumours.
The collaboration agreement will see eXmoor, an integrated cell and gene therapy contract development and manufacturing organisation, support Signadori in the transition from discovery through to good manufacturing practice (GMP)-compliant manufacturing of its lead candidate.
eXmoor will carry out a technology translation and development programme at its cell and gene therapy centre, as well as provide a Head of Chemistry, Manufacturing and Controls to join Signadori’s leadership team on an interim basis.
Signadori is currently advancing a platform designed to overcome the barriers...
Today's Sponsors
Today's Sponsor